SCI Abstract

search
+
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC
Chemotherapy-based regimens remain the standard-of-care first-line treatment for the large proportion of patients with adv...
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders
Chimeric antigen receptor (CAR) T cell therapy is now widely used for the treatment of various haematological malignancies...
Time as an unmeasured ‘dose’ in oncology: introducing time budgeting as a design principle for cancer care
The burden of cancer therapy on patients’ time is often overlooked. Building on the ‘time toxicity’ lite...
Systemic induction therapy and the expanding frontier of bladder preservation in MIBC
Two recent phase II trials, INDIBLADE and SURE-02, challenge the long-standing paradigm of mandatory radical local therapy...
Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer?
The ATOMIC trial has been widely celebrated as providing a positive result. However, when viewed with a lens of critical a...
Emerging trends in the global burden of colorectal cancer
Emerging trends in the global burden of colorectal cancer
Globally, colorectal cancer (CRC) is the third most frequently diagnosed cancer and the second leading cause of cancer-rel...
The clinical landscape of HIF2α inhibitors in oncology
The clinical landscape of HIF2α inhibitors in oncology
Hypoxia-inducible factor 2α (HIF2α; also known as endothelial PAS domain-containing protein 1) had long been con...
Synergistic integration of regional and systemic therapies in uveal melanoma
Treatments for metastatic uveal melanoma utilize various liver-directed strategies, yet optimal integration with systemic ...
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Immune-checkpoint inhibitors (ICIs) have improved clinical outcomes across several solid tumour types. Prominent efforts h...
Adding brentuximab vedotin to lenalidomide and rituximab improves OS in R/R DLBCL
Haematopoietic stem cell transplantation (HSCT) and CD19-targeted chimeric antigen receptor (CAR) T cells are potentially ...
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Circulating tumour DNA (ctDNA) can be released by cancer cells into biological fluids through apoptosis, necrosis or activ...
Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma
Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over...
Early promising results with addition of an ICI and an anti-angiogenic to TACE
Transarterial chemoembolization (TACE) is the standard-of-care treatment for patients with intermediate-stage hepatocellul...
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology
Paediatric acute myeloid leukaemia (AML) highlights the challenges of drug development for rare diseases, in which limited...
Thermal ablation is safer than resection of colorectal liver lesions
Surgical resection is the standard of care for patients with colorectal liver metastases. Thermal ablation has emerged as ...
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC
Two multimodal treatment strategies, perioperative chemotherapy and preoperative chemoradiotherapy, have been shown to imp...
Patients with uncommon EGFR mutations also benefit from first-line osimertinib
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
Recent results from the FLAURA2 and MARIPOSA-2 trials underline the continued role of chemotherapy in the treatment of pat...
Personalizing adjuvant therapy for patients with colorectal cancer
Personalizing adjuvant therapy for patients with colorectal cancer
The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC) comprises a fluoropyrim...
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients
Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the cur...
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell malignancies or relapsed and/or...
From the ESMO Congress 2023
As in 2017, this year’s ESMO Congress brought many members of the oncology community together in Madrid, this time with &g...
Computational immunogenomic approaches to predict response to cancer immunotherapies
Computational immunogenomic approaches to predict response to cancer immunotherapies
Cancer immunogenomics is an emerging field that bridges genomics and immunology. The establishment of large-scale genomic ...
THOR provides new data on the efficacy of erdafitinib
The outcomes of patients with metastatic urothelial carcinoma (mUC) and non-muscle invasive urothelial carcinoma (NMIBC) f...
Activity of selpercatinib confirmed in phase III trials
In May 2020, the FDA granted Accelerated Approval to the RET kinase inhibitor selpercatinib for patients with metastatic n...
From ESMO 2023: advances in lung cancer
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
From CHRYSALIS to PAPILLON: the metamorphosis of amivantamab into frontline therapy for NSCLC
In 2021, data from the phase I CHRYSALIS trial supported the FDA Accelerated Approval of amivantamab, an EGFR–MET bispecif...
Progress in systemic therapy for advanced-stage urothelial carcinoma
Progress in systemic therapy for advanced-stage urothelial carcinoma
Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable, with 5-year survival rates of approx...
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs
Projected increases of cancer-attributable health-care costs, accompanied by staff shortages, will impose future economic ...
Molecular tumour boards — current and future considerations for precision oncology
Molecular tumour boards — current and future considerations for precision oncology
Over the past 15 years, rapid progress has been made in developmental therapeutics, especially regarding the use of matche...
Load More
format_indent_increase